TABLE 2.
Risk Factors of ARP and CP by BMI Groups
| Underweight (n = 22) | Normal (n = 258) | Overweight (n = 75) | Obese (n = 91) | P | |
|---|---|---|---|---|---|
| Genetic mutations | |||||
| PRSS1 | 4/15 (26) | 63/188 (34) | 9/46 (20) | 15/62 (24) | 0.05 |
| SPINK1 | 2/14 (14) | 40/175 (23) | 5/42 (12) | 9/56 (16) | 0.12 |
| CFTR | 3/15 (20) | 62/185 (33) | 15/46 (34) | 14/62 (23) | 0.28 |
| CTRC | 0/9 (0) | 7/121 (6) | 0/27 (0) | 4/39 (10) | 0.77 |
| Obstructive factors | 6/22 (27) | 81/257 (32) | 19/73 (26) | 30/90 (33) | 0.87 |
| Pancreas divisum | 0/21 (0) | 31/251 (12) | 7/72 (10) | 11/84 (13) | 0.88 |
| Sphincter of Oddi disorders | 1/20 (5) | 5/244 (2) | 2/70 (3) | 3/88 (3) | 0.66 |
| Gallstones | 2/21 (10) | 11/252 (4) | 3/70 (4) | 5/89 (6) | 0.92 |
| Pancreaticobiliary malunion | 1/20 (5) | 9/250 (4) | 1/72 (1) | 3/88 (3) | 0.54 |
| Traumatic PD stricture | 1/21 (5) | 1/254 (0.4) | 0/71 (0) | 0/86 (0) | 0.19 |
| Duodenal diverticulum | 0/21 (0) | 1/253 (0.4) | 0/72 (0) | 0/87 (0) | 1.0 |
| Duct obstruction | 0/20 (0) | 5/255 (2) | 1/72 (1) | 1/88 (1) | 0.67 |
| Annular pancreas | 0/21 (0) | 2/254 (1) | 0/72 (0) | 1/88 (1) | 1.0 |
| Biliary cyst | 0/20 (0) | 5/255 (2) | 2/55 (4) | 4/76 (5) | 0.11 |
| Toxic/metabolic factors | |||||
| Alcohol | 0/22 (0) | 5/257 (2) | 0/74 (0) | 2/90 (2) | 0.84 |
| Tobacco (active or passive) | 2/20 (10) | 23/253 (9) | 5/66 (8) | 9/86 (10) | 0.95 |
| Hypertriglyceridemia | 0/16 (0) | 8/228 (4) | 3/63 (5) | 8/73 (11) | 0.02 |
| Autoimmune pancreatitis | 0/17 (0) | 7/200 (4) | 3/57 (5) | 1/67 (18) | 0.88 |
| Other autoimmune diseases | 1/20 (5) | 21/244 (9) | 8/70 (11) | 4/86 (5) | 0.72 |
| Inflammatory bowel disease | 0/20 (0) | 4/243 (2) | 0/68 (0) | 0/85 (0) | 0.28 |
Denominators represent data available for each group; data expressed as n (%) unless otherwise specified.
Statistically significant values are in bold.
*
Cochran-Armitage trend test was used for statistical comparisons.
ARP indicates Acute Recurrent Pancreatitis; CP: Chronic Pancreatitis; PD: pancreatic duct; CFTR, cystic fibrosis transmembrane conductance regulator; PRSS1, cationic trypsinogen; CTRC, chymotrypsin C; SPINK1, serine protease inhibitor Kazal-type 1.